Novonesis (Novozymes A/S)
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance
Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, in exchange for a total cash consideration of EUR 1.5 billion. After more than 25 years of successful collaboration, a strategic repositioning at dsm-firmenich allowed this opportunity to materialize. This acquisition is aligned with Novonesis’ growth strategy and expands its presence across the animal biosolutions value chain. Financially, this transaction is accretive to revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies.
Please refer to attachment for more details.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
TCM Group A/S5.8.2025 08:13:25 CEST | Press release
TCM Group A/S: Major shareholder announcement
TCM Group A/S5.8.2025 08:13:25 CEST | Pressemeddelelse
TCM Group A/S: Storaktionærmeddelelse
Tallink Grupp5.8.2025 08:00:44 CEST | Press release
AS Tallink Grupp Statistics for July 2025
ING Group5.8.2025 08:00:00 CEST | Press release
Progress on share buyback programme
Purespring Therapeutics5.8.2025 08:00:00 CEST | Press release
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom